Company: AZN
Filing Date: 2025-11-06
Form Type: 6-K
Source: 0001654954-25-012630
Chunk: 17

Company: ASTRAZENECA PLC
Filing Date: 2025-11-06
Form: 6-K
Chunk 17
---
 |    113 |     16 |
| Repayment of obligations under leases                         |   -273 |   -233 |
| Movement in short-term borrowings                             |  1,382 |    572 |
| Payment of Acerta Pharma share purchase liability             |      - |   -833 |
| Net cash outflow from financing activities                    | -4,262 | -3,325 |
| Net increase/(decrease) in Cash and cash equivalents in the   
 period                                                        |  2,609 | -1,170 |
| Cash and cash equivalents at the beginning of the             
 period                                                        |  5,429 |  5,637 |
| Exchange rate effects                                         |     42 |    -32 |
| Cash and cash equivalents at the end of the period            |  8,080 |  4,435 |
| Cash and cash equivalents consist of:                         |        |        |
| Cash and cash equivalents                                     |  8,143 |  4,797 |
| Overdrafts                                                    |    -63 |   -362 |
|                                                               |  8,080 |  4,435 |

Notes to the Interim financial statements

Note 1: Basis of preparation and accounting policies

These unaudited Interim financial statements for the nine months ended 30 September 2025 have been prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting' (IAS 34), as issued by the International Accounting Standards Board (IASB), IAS 34 as adopted by the European Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of the United Kingdom's Financial Conduct Authority and with the requirements of the Companies Act 2006 as applicable to companies reporting under those standards.

The unaudited Interim financial statements for the nine months ended 30 September 2025 were approved by the Board of Directors for publication on 6 November 2025.

This results announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 31 December 2024 were prepared in accordance with UK-adopted international accounting standards and with the requirements of the Companies Act 2006. The annual financial statements also comply fully with IFRS Accounting Standards as issued by the IASB and International Accounting Standards as adopted by the European Union. Except